MB
JANX icon

MPM BioImpact’s Janux Therapeutics JANX Stock Holding History

MPM BioImpact’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-614,282
Closed -$15M – 44
2025
Q3 		$15M Hold
614,282
– – 2.46% 18
2025
Q2 		$14.2M Buy
614,282
+47,089
+8% +$1.24M 2.46% 17
2025
Q1 		$15.3M Buy
567,193
+337,193
+147% +$12.7M 2.63% 15
2024
Q4 		$12.3M Buy
230,000
+58,895
+34% +$3.12M 1.75% 28
2024
Q3 		$7.77M Buy
+171,105
New +$7.44M 1.17% 27

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MPM BioImpact's JANX Position: Q4 2025 in Review

MPM BioImpact sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 614,282 shares — an estimated $15M sold.

MPM BioImpact first reported a position in JANX in Q3 2024 and held it in 5 quarters. The position peaked at $15.3M in Q1 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • MPM BioImpact reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 614,282 Janux Therapeutics shares in Q4 2025, an estimated $15M.
  • MPM BioImpact first reported a position in Janux Therapeutics in Q3 2024 and held it in 5 quarters.
  • MPM BioImpact's Janux Therapeutics position peaked at $15.3M in Q1 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.